Home / Sensory organs / Aflibercept
ATC S01LA05 · Antineovascularisation Agents
Aflibercept shortage
As of 2 Nov 2026, Aflibercept has a reported shortage in 2 of the 16 countries we track (Norway, Sweden), covering 4 products from 2 companies.
Countries2/16
Products4packs or presentations
Companies21 listed
Short since25 Sep 202638 days ago
Earliest return24 Nov 2026company estimate
Main reasonCommercial decision or withdrawal
United StatesNo reported shortageCanadaNo reported shortageGermanyNo reported shortageFranceNo reported shortageItalyNo reported shortageSpainNo reported shortageIrelandNo reported shortageAustriaNo reported shortageBelgiumNo reported shortageSwitzerlandNo reported shortageCzechiaNo reported shortageNorway2 products shortSweden2 products shortJapanNo reported shortageNew ZealandNo reported shortageAustraliaNo reported shortage
Timeline
NorwaySweden
Solid bars run from the reported start to today; faded bars show the time left until the expected return. An arrow means no return date was given.
Which companies are short
products short, all countriesListed: Bayer BAYN · Xetra
Compared with similar medicines
ATC group S01LA · Antineovascularisation AgentsAffected products
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| NO | Eylea 40 mg/ml injeksjonsvæske, oppløsning, 0 ml ferdigfylt sprøyte | Bayer AG | 16 Oct 2026 | 30 Sep 2027 | Commercial decision or withdrawal Planlagt utfasing/avregistrering |
| NO | Eylea 40 mg/ml injeksjonsvæske, oppløsning, 0 ml hetteglass | Bayer AG | 16 Oct 2026 | 24 Nov 2026 | Commercial decision or withdrawal Planlagt utfasing/avregistrering |
| SE | Eylea 40 mg/ml Injektionsflaska, 1 dos | Bayer AG | 25 Sep 2026 | 1 Dec 2026 | Not stated |
| SE | Opuviz 40 mg/ml Förfylld spruta, 0.1 ml anticipated | Samsung Bioepis NL B.V. | 1 Jan 2027 | 1 Jun 2027 | Not stated |
"Expected back" is the date the company gave the authority, when it gave one. Ask a pharmacist about alternatives.